Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Exelixis (EXEL)
NASDAQ:EXEL
Holding EXEL?
Track your performance easily
EXEL Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$18.64 - $27.83
Previous Close$26.82
Volume1.44M
Average Volume (3M)1.76M
Market Cap
$7.69B
Enterprise Value$6.85B
Total Cash (Recent Filing)$1.00B
Total Debt (Recent Filing)$198.02M
Price to Earnings (P/E)23.0
Beta0.54
Next Earnings
Oct 30, 2024EPS Estimate
$0.34Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.17
Shares Outstanding285,251,725
10 Day Avg. Volume1,572,716
30 Day Avg. Volume1,764,284
Standard Deviation0.11
R-Squared0.07
Alpha0.00327
Financial Highlights & Ratios
Price to Book (P/B)3.61
Price to Sales (P/S)3.91
Price to Cash Flow (P/CF)16.50
P/FCF Ratio17.40
Enterprise Value/Market CapN/A
Enterprise Value/Revenue3.40
Enterprise Value/Gross Profit3.90
Enterprise Value/Ebitda15.01
Forecast
1Y Price Target
$28.40Price Target Upside5.34% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering16
Exelixis News
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe final results from the Phase 3 CABINET trial showed cabozantinib significantly reduced the risk of disease progression or death in patients with neuroendocrine tumors.
Financial PerformanceCabozantinib revenues were $437.6mn, beating consensus by ~5%, driven by an increase in sales volume.
Regulatory ApprovalsThe FDA accepted the supplemental New Drug Application for cabozantinib and assigned a review date.
Bears Say
Clinical TrialsThe second Ph3 CONTACT-02 (mCRPC) OS analysis was not statistically significant.
Intellectual PropertyApproval remains a risk and cabo's IP trial needs to be resolved for EXEL to get credit.
Regulatory ApprovalEXEL will not pursue a regulatory path for cabo + nivo + ipi in 1L RCC due to the lack of an OS benefit at final analysis in the COSMIC-313 trial.
---
Ownership Overview
4.37% Insiders
29.05% Mutual Funds
53.44% Other Institutional Investors
13.15% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
EXEL FAQ
What was Exelixis’s price range in the past 12 months?
Exelixis lowest stock price was $18.64 and its highest was $27.83 in the past 12 months.
What is Exelixis’s market cap?
Currently, no data Available
When is Exelixis’s upcoming earnings report date?
Exelixis’s upcoming earnings report date is Oct 30, 2024 which is in 41 days.
How were Exelixis’s earnings last quarter?
Exelixis released its earnings results on Aug 06, 2024. The company reported $0.77 earnings per share for the quarter, beating the consensus estimate of $0.31 by $0.46.
Is Exelixis overvalued?
According to Wall Street analysts Exelixis’s price is currently Undervalued.
Does Exelixis pay dividends?
Exelixis does not currently pay dividends.
What is Exelixis’s EPS estimate?
Exelixis’s EPS estimate is $0.34.
How many shares outstanding does Exelixis have?
Exelixis has 285,251,740 shares outstanding.
What happened to Exelixis’s price movement after its last earnings report?
Exelixis reported an EPS of $0.77 in its last earnings report, beating expectations of $0.31. Following the earnings report the stock price went up 13.092%.
Which hedge fund is a major shareholder of Exelixis?
Among the largest hedge funds holding Exelixis’s share is Farallon Capital Management, L.L.C.. It holds Exelixis’s shares valued at 609M.
---
Exelixis Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$28.40 (5.34% Upside)
$28.40 (5.34% Upside)
Blogger Sentiment
Bullish
EXEL Sentiment 94%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 387.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $5.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.6%
Last 30 Days ▲ 4.6%
Last 30 Days ▲ 4.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
25.62%
12-Months-Change
Fundamentals
Return on Equity
15.06%
Trailing 12-Months
Asset Growth
-11.75%
Trailing 12-Months
Company Description
Exelixis
Exelixis, Inc. is a biopharmaceutical company, which engages in the development, commercialization, and discovery of new medicines for the treatment of cancer. It offers products under the brands of Cometriq, Cabometyx, and Cotellic. The company was founded by Corey S. Goodman and Stelios B. Papadopoulos on November 15, 1994 and is headquartered in Alameda, CA.
---
EXEL Company Deck
---
EXEL Earnings Call
Q2 2024
0:00 / 0:00
---
EXEL Revenue Breakdown
89.00% Net product revenues
9.76% License revenues
1.24% Collaboration services revenues
---
EXEL Stock 12 Month Forecast
Average Price Target
$28.40
▲(5.34% Upside)
Technical Analysis
Best Analysts Covering EXEL
1 Year
1 Year Success Rate
14/14 ratings generated profit
1 Year Average Return
+21.87%
reiterated a buy rating 16 days ago
Copying Jason Gerberry's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +21.87% per trade.
---